

IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of the claims:

Claims 1-9 (**cancelled**).

Claim 10 (**currently amended**): A pharmaceutical composition which comprises AZD2171 (4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline) or a pharmaceutically acceptable salt thereof, and a taxane in association with a pharmaceutically acceptable excipient or carrier.

Claim 11 (**cancelled**).

Claim 12 (**currently amended; withdrawn**): A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of AZD2171 (4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline) or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of a taxane.

Claim 13 (**currently amended; withdrawn**): A method for the production of an antiangiogenic and/or vascular permeability reducing effect in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of AZD2171 (4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline) or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of a taxane and before, after or simultaneously with an effective amount of ionising radiation.

Claim 14 (**withdrawn**): The method according to any one of claims 12, 13, 17 and 18 wherein AZD2171 is in a form of the free base.

Claim 15 (**withdrawn**): The method according to any one of claims 12, 13, 17 and 18 wherein the taxane is paclitaxel.

Claim 16 (**withdrawn**): The method according to any one of claims 12, 13, 17 and 18 wherein the taxane is docetaxel.

Claim 17 (**currently amended; withdrawn**): A method for treating a cancer involving a solid tumour in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of AZD2171 (4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline) or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of a taxane.

Claim 18 (**currently amended; withdrawn**): A method for treating a cancer involving a solid tumour in a warm-blooded animal in need thereof, which comprises administering to said animal an effective amount of AZD2171 (4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline) or a pharmaceutically acceptable salt thereof, before, after or simultaneously with an effective amount of a taxane and before, after or simultaneously with an effective amount of ionising radiation.

Claim 19 (**previously presented**): The pharmaceutical composition according to claim 10 wherein the AZD2171 comprises a salt of AZD2171.

Claim 20 (**previously presented**): The pharmaceutical composition according to claim 19 wherein the salt of AZD2171 comprises AZD2171 maleate salt.

Claim 21 (**previously presented**): The pharmaceutical composition according to claim 10 wherein the AZD2171 comprises AZD2171 free base.

Claim 22 (**currently amended**): The pharmaceutical composition according to any one of claims 10 and 19-21 wherein the taxane is selected from the group consisting of paclitaxel and docetaxel.

Claim 23 (**previously presented**): The pharmaceutical composition according to claim 22 wherein the taxane is docetaxel.

Claim 24 (**withdrawn**): The pharmaceutical composition according to claim 22 wherein the taxane is paclitaxel.